Advancing Cancer Care for Dogs

Peer Reviewed by Nature™: Remarkable Survival Gains for Canine Cancer Patients. See how we work with:

0 B
Canine Cancer Data Points
0 x
Overall Survival Rate
0 %+
Third Key Statistic
0
Fourth Key Statistic

We are transforming canine cancer care through ongoing scientific research and innovation in therapeutic treatments.

Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics​

New approaches to the development of cancer therapeutics are urgently needed to improve the current 89% failure rate of novel drugs in clinical trials, and to improve patient outcomes. Spontaneous cancer in companion animals represents a unique opportunity for investigation of novel therapeutics for human and veterinary use

Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs​

Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials

Dog cancer research advances pursuit of drugs for humans and canines​

Published June 19, 2023 | Compelling genetic data, increased funding and growing collaborations in the past decade are pushing forward development of cancer drugs for both canines and humans

Could Fido lead us to better cancer drugs?​

Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials

World’s largest genomic study of canine cancer reveals potential for novel human cancer treatments​

Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.

There’s no “one-size-fits-all” treatment for cancer. That’s why FidoCure® uses genomic testing to determine the best course of action for your dog’s cancer therapy – beyond standard chemo and radiation.

FidoCure® Approach: Genetic testing reveals which targeted therapies may work best for your dog

Precision medicine can offer a hopeful prognosis.  FidoCure® was created by dog lovers and scientists on a mission to make effective canine cancer treatment accessible.  Our process uses genomic testing in conjunction with tumor type to identify possible cancer-causing mutations. From there, we suggest targeted therapy to precisely attack the cancer cells.

Forrest was diagnosed with splenic cancer and given one month to live.

Through the targeted therapy suggested by FidoCure®, he lived happily for nearly 4 years past his diagnosis.

“Thank you for your support and for opening the door to those four wonderful extra years.”
— Grace , CT

Forrest, Golden Retriever

Hemophagocytic Histiocytic Sarcoma

Thousands of dogs have benefited from FidoCure® when other options were limited.

Resources & Education